Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhalation device for inhalation use. It provides bronchodilation for patients with reversible airway obstruction. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic respiratory diseases.

- Asthma: improves symptom control and reduces the need for rescue inhaler use. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases exacerbation frequency. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Formoterol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient headache episodes. - Throat irritation: discomfort or dryness in the throat. - Cough: occasional dry cough after inhalation. - Palpitations: awareness of heartbeat acceleration. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airway obstruction. - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose in susceptible individuals. - Pulmonary hypertension: increased pressure in lung arteries (very rare).

When prescribing Formoterol, clinicians should consider patient‑specific factors and follow safe handling practices.

- Assess cardiovascular risk: evaluate history of arrhythmia, hypertension, or coronary disease. - Review asthma/COPD control: ensure the patient is on an appropriate maintenance regimen. - Avoid abrupt discontinuation: taper if switching from high‑dose inhaled steroids. - Monitor for paradoxical bronchospasm: educate patients to seek help if symptoms worsen after use. - Caution in pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Formoterol can interact with several drug classes, altering its safety profile or efficacy.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia. - Theophylline: additive bronchodilator effect, monitor serum levels. - Anticholinergic inhalers: combined use may increase anticholinergic load. - β‑agonist‑containing combination inhalers: avoid excessive β2 stimulation. - Certain antidepressants (e.g., SSRIs): may modestly raise heart rate.